Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis.

doi:10.1038/sj.gene.6364228

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis.

Genes and immunity - 1 Sept 2005

Camp N J, Cox A, di Giovine F S, McCabe D, Rich W, Duff G W

Abstract excerpt

Biological activity of the IL-1 system depends on the balance between two proinflammatory proteins (IL-1alpha and IL-1beta) and the related anti-inflammatory protein, the IL-1 receptor antagonist (IL-1Ra). The genes for these proteins lie within 430 kb on human chromosome 2. Based on a clinical trial of human recombinant IL-1ra in rheumatoid arthritis, we tested whether IL-1 genotype might be related to the...

Topics

Alleles
Arthritis, Rheumatoid
Double-Blind Method
Drug Resistance
Genotype
Humans
Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Polymorphism, Single Nucleotide
Recombinant Proteins
Sialoglycoproteins

Source

Open in PubMed

Identifiers

PMID: 15931231
DOI: 10.1038/sj.gene.6364228

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics